Speech-Language Pathologists in Pinckneyville, IL Accepting Medicare

2 Speech-Language Pathologists found. Showing 1 - 2

Mrs. Lori Reeds Waggoner, MS CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 301 W Mulberry St, Pinckneyville, IL 62274 Phone: 618-357-5161    Fax: 618-357-9431

Elizabeth Forsberg Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 101 N. Walnut, Pinckneyville Community Hospital, Pinckneyville, IL 62274 Phone: 618-357-2187    Fax: 618-357-6336

News Archive

FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante

BioSante Pharmaceuticals, Inc. commented today that the recommendation on June 18, 2010 by the FDA Advisory Committee regarding the safety and efficacy of flibanserin (Boehringer-Ingelheim) will have no impact on its own ongoing development program or approval pathway for LibiGel (testosterone gel), for the treatment of hypoactive sexual desire disorder (HSDD).

Disruption of immune cell behavior may spur heart disease, heart failure

On an ice hockey team, the players all start off with identical uniforms, skates and a stick. But if you take one of them, add padding, a glove, and a mask; and switch the stick to one with a larger blade, then you get a goalie.

Pevion launches Defensomes platform for broad spectrum immune enhancement

Pevion Biotech AG today announced the launch of a new program called Defensomes, a platform for broad spectrum immune enhancement via mechanisms of innate immunity. The proprietary technology is derived from a vaccine platform with a solid safety track record comprising more than 80 million doses applied to humans to date. Defensomes offer opportunities for a wide range of prophylactic and therapeutic indications, where boosting of the body's own natural defense is beneficial.

Report outlines steps for transition of PEPFAR service delivery to S. African government

The Center for Strategic & International Studies' "Smart Global Health" blog highlights a report called "Terra Nova: How to Achieve a Successful PEPFAR Transition in South Africa," writing, "The United States and South Africa are negotiating a complex, multi-year handoff that will shift financial and managerial responsibilities for HIV/AIDS to the South African government and move the United States away from direct service delivery and into technical assistance.

Multaq approved for atrial fibrillation by FDA

Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.

Read more Medical News

› Verified 8 days ago